Human MET/AUTS9/ DA11 ORF/cDNA clone-Lentivirus particle (NM_001127500)

Pre-made Human MET/AUTS9/ DA11 Lentiviral expression plasmid for MET lentivirus packaging, MET lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

The GM Vector Core (GMVC) specializes in custom lentivirus development and offers a range of lentivirus manufacturing solutions, leveraging state-of-the-art processes. Learn more about our services.

Target products collectionGo to MET/AUTS9 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Product information

Catalog No. Product Name lentivirus Grade lentivirus quantity
vGMLV000394 Human MET Lentivirus particle Pilot Grade 1.0E+8TU
Research Grade 1.0E+8TU
GMP-like Grade inquiry
GMP Grade inquiry

Product Description

Catalog ID vGMLV000394
Gene Name MET
Accession Number NM_001127500
Gene ID 4233
Species Human
Product Type Lentivirus particle (overexpression)
Insert Length 4227 bp
Gene Alias AUTS9, DA11, DFNB97, HGFR, RCCP2, c-Met
Fluorescent Reporter ZsGreen
Mammalian Cell Selection Puromyocinmyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin


    Data / case study

    Click to get more Data / Case study about the product.

    Associated products

    Category Cat No. Products Name
    Biosimilar GMP-Bios-ab-021 Pre-Made Amivantamab biosimilar, Bispecific mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
    Biosimilar GMP-Bios-ab-178 Pre-Made Emibetuzumab biosimilar, Whole mAb, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
    Biosimilar GMP-Bios-ab-656 Pre-Made Bafisontamab biosimilar, Whole mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
    Biosimilar GMP-Bios-ab-401 Pre-Made Onartuzumab biosimilar, Fab + di-Fc, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
    Biosimilar GMP-Bios-ab-559 Pre-Made Telisotuzumab biosimilar, Whole mAb ADC, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
    Biosimilar GMP-Bios-INN-1017 Pre-Made Telisotuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Met Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody Drug Conjugate
    Target Antibody GM-Tg-g-T40474-Ab Anti-MET/ AUTS9/ DFNB97 monoclonal antibody
    Target Antigen GM-Tg-g-T40474-Ag MET VLP (virus-like particle)
    ORF Viral Vector pGMLV000394 Human MET Lentivirus plasmid
    ORF Viral Vector vGMLV000394 Human MET Lentivirus particle

    Target information

    Target ID GM-T40474
    Target Name MET
    Gene ID 4233, 17295, 704562, 24553, 493669, 403438, 280855, 100056013
    Gene Symbol and Synonyms AUTS9,c-Met,DA11,DFNB97,HGF,HGFR,MET,Par4,RCCP2
    Uniprot Accession P08581
    Uniprot Entry Name MET_HUMAN
    Protein Sub-location Transmembrane Protein
    Category Therapeutics Target, Immuno-oncology Target, INN Index
    Disease Non-Small Cell Lung Cancer, Breast Cancer, gastric cancer
    Gene Ensembl ENSG00000105976
    Target Classification Checkpoint-Immuno Oncology, Kinase

    This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]

    About GMVC


    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.